IPO - Nexalin Technology, Inc.

Form Type: 424B4

Filing Date: 2025-05-06

Corporate Action: Ipo

Type: New

Accession Number: 000182912625003425

Filing Summary: Nexalin Technology, Inc. has announced a public offering of 3,850,000 shares of its common stock at a price of $1.30 per share, aiming to raise approximately $5,005,000 before expenses. The offering is conducted under Rule 424(b)(4) as a registration statement on Form S-3 that became effective on April 29, 2025. The shares are listed on The Nasdaq Capital Market under the symbol 'NXL,' with the last reported sales price being $1.33. The company, classified as an 'emerging growth company,' is subject to reduced reporting requirements signified by the JOBS Act. Details regarding underwriting discounts, net proceeds, and additional shares were discussed, including an overallotment option for underwriters for up to 577,500 additional shares. The proceeds from this offering will be allocated for working capital and corporate purposes, alongside a discussion of risks involved in investing, particularly those related to capital stock and operational compliance with Nasdaq requirements.

Form Type: 8-K

Filing Date: 2025-05-06

Corporate Action: Ipo

Type: New

Accession Number: 000182912625003427

Filing Summary: Nexalin Technology, Inc. entered into an underwriting agreement with Maxim Group LLC on May 4, 2025, related to an offering of 3,850,000 shares of its common stock, with a public offering price set at $1.30 per share. The offering is anticipated to close on May 6, 2025, subject to customary conditions. The company will pay the underwriters an 8% fee on gross proceeds, along with up to $110,000 in expense reimbursement. The shares are registered under a Form S-3 that was declared effective on April 29, 2025. A press release announcing the pricing of the offering was issued on May 5, 2025, and attached to this report as an exhibit.

Form Type: 424B4

Filing Date: 2025-05-02

Corporate Action: Ipo

Type: New

Accession Number: 000182912625003319

Filing Summary: Nexalin Technology, Inc. is conducting an initial public offering (IPO) of shares of its common stock under a preliminary prospectus supplement filed with the SEC. The offering is made under an effective registration statement, with details related to the number of shares and pricing to be determined. The company emphasizes that investing in its common stock carries a high degree of risk and indicates that no sales have been made under certain SEC instructions prior to this supplemental prospectus. The company, structured as an emerging growth company, plans to use proceeds from this offering for general corporate purposes including working capital, product development, and marketing activities. The document outlines the company's operational challenges with respect to FDA classifications and marketing strategies for its medical devices amidst compliance requirements from Nasdaq. As of May 2025, the company had a market value approximated with shares trading under the Nasdaq symbol “NXL.”

Form Type: 8-K

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000182912625000757

Filing Summary: On February 3, 2025, the Registration Statement on Form S-1 filed by Nexalin Technology, Inc. was declared effective by the SEC. This Registration Statement covers up to 2,798,613 shares of the Company's common stock. It includes 347,250 shares issuable from warrants issued to Maxim Partners, LLC for their role in the Company’s 2022 IPO, 2,315,000 shares from warrants associated with the Company’s 2022 public offering, and 136,363 shares issued to Maxim Partners under a renewed engagement agreement. All warrants are exercisable at a price of $4.15 per share.

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: Update

Accession Number: 000182912625000571

Filing Summary: Nexalin Technology, Inc. filed an amendment to its S-1 registration statement on January 30, 2025, to facilitate the resale of up to 2,798,613 shares of common stock. The shares consist of three components: 347,250 shares from common stock purchase warrants issued to Maxim Partners as compensation for services related to the 2022 IPO, 2,315,000 shares from purchase warrants issued during the 2022 public offering of Units, and 136,363 shares issued to Maxim Partners under a renewed engagement agreement. The warrants are immediately exercisable but will expire three years after being issued, and the holders may sell their shares on market or negotiated terms. The document emphasizes that Nexalin offers no proceeds from the shareholders' resale but will benefit from any exercised warrants for cash. The company has been classified as a smaller reporting and emerging growth company. The current market trading price of its stock as of January 29, 2025, is $2.60 per share. Additionally, the document outlines the company's focus on developing neurostimulation products to address mental health issues, including ongoing developments regarding its medical devices and the regulatory processes with the FDA. The company has halted new marketing efforts for its existing 'Gen-1' devices due to recent FDA reclassifications.

Form Type: S-1/A

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: Update

Accession Number: 000182912625000158

Filing Summary: Nexalin Technology, Inc. is amending its Form S-1 registration statement to facilitate the resale of up to 2,798,613 shares of common stock by selling stockholders, which includes shares issuable upon the exercise of common stock purchase warrants related to its 2022 public offering and initial public offering. The company continues to pursue FDA approval for its Generation 2 and Generation 3 neurostimulation devices, which utilize an advanced waveform designed to treat mental health conditions without drugs or psychotherapy. The company is currently classified as an emerging growth company and is subject to reduced reporting requirements. No underwriters were engaged to facilitate sales, and the selling stockholders will bear any selling expenses. The stock was last priced at $2.97 per share as of January 9, 2025. The document outlines risks associated with investing in their securities, the planned use of proceeds, and the regulatory pathway related to their innovative products.